Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain

Journal of Clinical Microbiology

Volumn 40, Issue 10, 2002, Pages 3865-3866

  Gallego, Oscar ^a   Ruíz, Lidia ^a   Vallejo, Alex ^a   Clotet, Bonaventura ^a   Leal, Manuel ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SPAIN; TREATMENT FAILURE; VIROLOGY; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENE FREQUENCY; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; SPAIN; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0036792286     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.10.3865-3866.2002     Document Type: Article

References (12)

1. Carpenter, C. C. J., D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. Volberding. 2000. Antiretroviral therapy in adults: update recommendations of the International AIDS Society-USA panel. JAMA 283:381-390.
2. Coakley, E., J. Gillis, and S. Hammer. 2000. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F16.
3. Friedland, G., and L. Andrews. 2001. Adherence to antiretroviral therapy. AIDS Rev. 3:111-120.
4. Gallego, O., L. Ruiz, A. Vallejo, E. Ferrer, A. Rubio, B. Clotet, M. Leal, V. Soriano, and the ERASE-3 Group. 2001. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 15:1894-1896.
5. Gómez-Cano, M., A. Rubio, T. Puig, M. Pérez-Olmeda, L. Ruiz, V. Soriano, J. A. Pineda, L. Zamora, N. Xaus, B. Clotet, and M. Leal. 1998. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 12:1015-1020.
6. Hertogs, K., S. Bloor, V. De Vroey, and B. Larder. 2000. A novel HIV-1 RT mutational pattern confers phenotypic lamivudine resistance in the absence of mutation M184V. Antimicrob. Agents Chemother. 44:568-573.
7. Hirsch, M., F. Brun-Vèzinet, R. D'Aquila, S. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV infection. JAMA 283:2417-2426.
8. International AIDS Society-USA Resistance Testing Panel. 2001. Antiretroviral resistance mutations. HIV Clin. Trials 2:346-355.
9. Izopet, J., A. Bicart-See, and C. Pasquier. 1999. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J. Med. Virol. 59:507-511.
10. Miller, V., M. Ait-Khaled, and C. Stone. 2000. HIV-1 RT genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14:163-171.
11. Pérez-Olmeda, M., J. Del Romero, A. Rubio, L. Ruiz, C. Rodriguez, M. Leal, B. Clotet, and V. Soriano. 2001. Prevalence of drug resistance in Spain before and after the introduction of protease inhibitors. J. Med. Virol. 63:85-90.
12. Puig, T., M. Pérez-Olmeda, A. Rubio, L. Ruiz, C. Briones, J. M. Franco, M. Gómez-Cano, L. Stuyver, L. Zamora, C. Alvarez, M. Leal, B. Clotet, V. Soriano, and the ERASE-2 Study Group. 2000. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS 14:727-732.